Fennec Pharmaceuticals Inc faces a challenging day on the TSX as its stock slips 1.25%.
Fennec Pharmaceuticals Inc (FRX.TO) saw its stock price drop during the last trading session, closing at CA$12.69, down 1.25%. This decline raises questions about the company's current position and future in the competitive pharmaceutical landscape.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$503.69M
52W high
$15.48
52W low
$7.59
1W change
-5.35%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 545.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+545.3% Upside
Current Price
C$14.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
51.2%
Annualized
90-Day Vol
86.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$17.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$15.39 | C$12.90 – C$18.37 |
| 60 trading days | C$16.33 | C$12.72 – C$20.97 |
| 90 trading days | C$17.33 | C$12.76 – C$23.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should stay alert as Fennec Pharmaceuticals deals with market pressures, especially given recent performance trends and the lack of significant news to boost confidence.
Market Cap: CA$446.37 Million
With a market cap of CA$446.37 million, Fennec Pharmaceuticals operates in a competitive sector, making it essential for the company to maintain investor trust amid fluctuating stock performance.
Bull case
Despite today’s downturn, Fennec has shown strong revenue growth and positive results from clinical studies in the past. This suggests there’s potential for recovery and long-term success.
Bear case
The absence of recent news or developments could indicate stagnation, and the current market sentiment may reflect broader concerns about the company’s ability to sustain its growth.
Market Performance Overview
Fennec Pharmaceuticals Inc's stock closed down 1.25% in the last trading session, reflecting investor uncertainty. With no significant news to drive interest, this decline may signal a broader market trend affecting biotech stocks.
Company Fundamentals
Fennec Pharmaceuticals has a market cap of CA$446.37 million, but its profit margin is negative at -0.1642. Investors should weigh these financial metrics when considering the company's potential for recovery.
Looking Ahead
As Fennec Pharmaceuticals navigates the market, investors should keep an eye on upcoming announcements and financial reports. The lack of recent news may impact investor sentiment, making it crucial for the company to effectively communicate its strategic direction.
Advertisement
